Analysts expect that Ekso Bionics Holdings Inc (NASDAQ:EKSO) will report earnings of ($0.04) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ekso Bionics’ earnings. Ekso Bionics reported earnings of ($0.07) per share in the same quarter last year, which would suggest a positive year over year growth rate of 42.9%. The firm is scheduled to announce its next earnings results on Thursday, February 27th.
On average, analysts expect that Ekso Bionics will report full-year earnings of ($0.21) per share for the current financial year, with EPS estimates ranging from ($0.24) to ($0.18). For the next fiscal year, analysts forecast that the business will report earnings of ($0.16) per share, with EPS estimates ranging from ($0.18) to ($0.13). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Ekso Bionics.
Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Wednesday, October 30th. The company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The business had revenue of $3.32 million for the quarter. Ekso Bionics had a negative net margin of 100.36% and a negative return on equity of 376.63%.
Shares of NASDAQ:EKSO remained flat at $$0.38 during trading on Wednesday. 780,247 shares of the stock were exchanged, compared to its average volume of 1,564,881. The company has a market capitalization of $28.49 million, a price-to-earnings ratio of -1.82 and a beta of 1.44. The business’s 50-day simple moving average is $0.43 and its two-hundred day simple moving average is $0.67. Ekso Bionics has a fifty-two week low of $0.35 and a fifty-two week high of $2.55. The company has a quick ratio of 1.69, a current ratio of 2.11 and a debt-to-equity ratio of 0.28.
Large investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its position in shares of Ekso Bionics by 4,401.9% during the second quarter. Wells Fargo & Company MN now owns 49,521 shares of the company’s stock worth $63,000 after acquiring an additional 48,421 shares during the period. BlackRock Inc. increased its position in shares of Ekso Bionics by 123.2% during the second quarter. BlackRock Inc. now owns 813,996 shares of the company’s stock worth $1,035,000 after acquiring an additional 449,348 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Ekso Bionics by 41.2% during the second quarter. Vanguard Group Inc. now owns 2,085,186 shares of the company’s stock worth $2,648,000 after acquiring an additional 608,759 shares during the period. 33.41% of the stock is currently owned by institutional investors and hedge funds.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Read More: What are the benefits of investing in REITs?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.